Objectively speaking, from the perspective of the efficacy nail salon hong kong. safety, economy and theoretical fund tolerance of some of these products, it is not very reasonable to be so one-size-fits-allnail salon hongkong. But I understand very well that the medical insurance will adopt this seemingly unreasonable solution. A major feature of this catalogue is that the various insulins are listed directly in the catalogue, instead of taking the previous examples and explaining themnail salon hongkong. Personally, this is actually more straightforward, especially before the country has yet to harmonize the Medicare drug code. It is also convenient and convenient to handle the application of your own codenail salon hongkong. Personal reasoning is mainly because of the price factor, that is, the medical insurance party has calculated that the use of these drugs will increase the burden of the medical insurance fund to some extent than the use of similar drugs. Due to the lack of corresponding clinical evidencenail salon hongkong, these products have increased the number of days of use, which is also to prevent abuse. Objectively speaking, compared with the products that focus on monitoring the catalogue, the catalogue is directly removed, and it is still merciless. Howevernail salon hongkong, the price is actually much more expensive than oral products, and it is a pity that there is no negotiation opportunity because of the imitation of the product. On the other hand, this product is relatively expensive compared to similar products. Overall, products with higher prices than similar products are more likely to attract more stringent indications. In my opinion, it is quite reasonable. On the one hand, it is in line with the guidelines. Second, some of these drugs are still quite expensive. There is also a risk of abuse in the clinic. EPO has increased the indication for anemia caused by chemotherapy for non-myeloid malignant tumors. This indication should not be approved for a long time. It is quite fast to add to the catalogue. I personally think that these points are actually not a problem. One of the purposes of the negotiations is to cut prices, or to realize value purchase. If it is too expensive or not economical, medical insurance will not buy it. In terms of efficacy and safety, these two products are due to Not an exclusive product, several manufacturers have maintained a high price, so this time I am very sorry that I have no medical insurance. Since these two products have a lot of local medical insurance directory access or negotiation records, they will definitely have some impact on patients’ medication. The prices of domestically produced imitation products of these three products have dropped a lot, so it is understandable that the restrictions on indications are relaxed. What’s more, perhaps these products will be attended next year, and it is likely that there will be further sharp decline in prices. It is possible to reduce regional medical insurance differences from the height of the national level and further reduce the burden on patients.